Seems at this point, everything worth shorting is out and public...snap back could be very strong.
if trial results are good $18 will be too conservative...more like $30-40
Tutes are always scouring the listings of new NASDAQ stocks to beat the herd in.
so no reason to add to it. also putting shorts on notice that they have no guarantees, MIssling could come gunning for you at any moment. You wont get any warning of accelerated FDA approval or the 300% up day that will bring.
biggest piece of news will be that it has p2 results coming within days, and it is the only real alz drug that has shown potential for treatment.
if he mentioned it weeks in advance, shorts like Tic would be creating uncertainty for weeks. better to announce today and done tomorrow
nothing unusual. maybe better that the testing is outsourced, third party only interested in accurate results.
$100 a share with 40m shares is only a $4 billion market cap. Quite cheap if p2 results are very good and we get accelerated approval. Plenty of biotechs trading in that range.
they had no way of knowing what the RS ratio would be long ago when Missling got the 1m share bonus for hitting the milestone. It could be 1:4 or 1:7, so the logical implication is the 1m is presplit shares, and would be 250,000 after split
patients who would have been dead in 6 months without the vaccine....sickest of the sick metastatic cancer patients. Darn FDA should just have asked for data, no reason for hold.
and she survived several surgeries for car accident...so numerous surgeries after treatment and no effects of vaccine. FDA should have just asked for more data and not issued hold
yes two years for patients expected to live only 6 months or less without treatment
That is what I would hope. Dont really see a need for the hold, at least in people without prosthetic implants.